{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T07:40:09Z","timestamp":1748850009079,"version":"3.41.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"4-5","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.neurol.2015.12.010","type":"journal-article","created":{"date-parts":[[2016,4,7]],"date-time":"2016-04-07T10:11:55Z","timestamp":1460023915000},"page":"313-317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Implications of metabolic parameters of carbamazepine in the therapeutic monitoring of Tunisian patients with epilepsy"],"prefix":"10.1016","volume":"172","author":[{"given":"C.","family":"Chbili","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hassine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ben Amor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Nouira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ben Ammou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Saguem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2015.12.010_bib0005","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0920-1211(94)90056-6","article-title":"The influence of polytherapy on the relationships between serum carbamazepine and its metabolites in epileptic children","volume":"17","author":"Liu","year":"1994","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.neurol.2015.12.010_bib0010","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s002280050475","article-title":"A model for the determination of carbamazepine clearance in children on mono- and polytherapy","volume":"54","author":"Gray","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.neurol.2015.12.010_bib0015","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jpba.2004.11.058","article-title":"Liquid chromatography\/tandem mass spectrometry for the determination of carbamazepine and its main metabolite in rat plasma utilizing an automated blood sampling system","volume":"38","author":"Zhu","year":"2005","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.neurol.2015.12.010_bib0020","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s00216-006-0724-7","article-title":"Analysis of carbamazepine and its active metabolite, carbamazepine-10,11-epoxide, in human plasma using high-performance liquid chromatography","volume":"386","author":"Oh","year":"2006","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.neurol.2015.12.010_bib0025","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0731-7085(97)00265-3","article-title":"Simultaneous determination of phenytoin, carbamazepine, and 10,11-carbamazepine epoxide in human plasma by heigh-performance liquide chromatography with ultraviolet detection","volume":"16","author":"Bhatti","year":"1998","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.neurol.2015.12.010_bib0030","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s002130050524","article-title":"An active metabolite of carbamazepine, carbamazepine-10,11-epoxide, inhibits ion channel-mediated catecholamine secretion in cultured bovine adrenal medullary cells","volume":"135","author":"Yoshimura","year":"1998","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neurol.2015.12.010_bib0035","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0378-4347(01)00328-0","article-title":"Simultaneous high-performance liquid chromatography determination of carbamazepine and five of its metabolites in plasma of epileptic patients","volume":"762","author":"Mandrioli","year":"2001","journal-title":"J Chromatogr B"},{"key":"10.1016\/j.neurol.2015.12.010_bib0040","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.saa.2006.12.051","article-title":"PLS-based extractive spectrophotometric method for simultaneous determination of carbamazepine and carbamazepine-10,11-epoxide in plasma and comparison with HPLC","volume":"68","author":"Hemmateenejad","year":"2007","journal-title":"Spectrochimica Acta Part A"},{"key":"10.1016\/j.neurol.2015.12.010_bib0045","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0378-4347(96)00116-8","article-title":"High-speed liquid chromatographic method for the monitoring of carbamazepine and its active metabolite, carbamazepine-10,11-epoxide, in human plasma","volume":"683","author":"Chollet","year":"1996","journal-title":"J Chromatogr"},{"issue":"7","key":"10.1016\/j.neurol.2015.12.010_bib0050","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2015.12.010_bib0055","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.arcmed.2003.09.016","article-title":"Pharmacokinetic study of carbamazepine and its carbamazepine 10,11-epoxide metabolite in a group of female epileptic patients under chronic treatment","volume":"35","author":"Moreno","year":"2004","journal-title":"Arch Med Res"},{"issue":"4","key":"10.1016\/j.neurol.2015.12.010_bib0060","first-page":"453","article-title":"Relationships between pharmacokinetic parameters of carbamazepine and therapeutic response in patients with bipolar disease","volume":"72","author":"Chbili","year":"2014","journal-title":"Ann Biol Clin"},{"key":"10.1016\/j.neurol.2015.12.010_bib0065","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.yebeh.2014.09.069","article-title":"\u201cThe benefits of antiepileptic drug (AED) blood level monitoring to complement clinical management of people with epilepsy\u201d","volume":"42","author":"Stepanova","year":"2015","journal-title":"Epilepsy Behav"},{"issue":"1","key":"10.1016\/j.neurol.2015.12.010_bib0070","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1590\/S1676-26492006000100004","article-title":"Systemic and presystemic conversion of carbamazepine to carbamazepine-10,11-epoxide during long term treatment","volume":"12","author":"Pietro","year":"2006","journal-title":"J Epilepsy Clin Neurophysiol"},{"issue":"3","key":"10.1016\/j.neurol.2015.12.010_bib0075","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0920-1211(96)00011-3","article-title":"Dose-dependent metabolism of carbamazepine in humans","volume":"24","author":"Bernus","year":"1996","journal-title":"Epilepsy Res"},{"issue":"6","key":"10.1016\/j.neurol.2015.12.010_bib0080","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2125.1992.tb04089.x","article-title":"Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites","volume":"33","author":"Kudriakova","year":"1992","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.neurol.2015.12.010_bib0085","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/00007691-199812000-00012","article-title":"Carbamazepine-10,11-epoxide in therapeutic drug monitoring","volume":"20","author":"Potter","year":"1998","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.neurol.2015.12.010_bib0090","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0022-3565(25)21671-8","article-title":"Individual and combined antiepileptic and neurotoxic activity of carbamazepine and carbamazepine-10,11-epoxide in mice","volume":"231","author":"Bourgeois","year":"1984","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.neurol.2015.12.010_bib0095","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ana.410350616","article-title":"Seizure exacerbation and status epileptics related to carbamazepine-10,11-epoxide","volume":"35","author":"So","year":"1994","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.neurol.2015.12.010_bib0100","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1055\/s-2008-1073024","article-title":"The metabolization of carbamazepine to CBZ-10,11-epoxide in children from the newborn age to adolescence","volume":"25","author":"Korinthenberg","year":"1994","journal-title":"Neuropediatrics"},{"issue":"6","key":"10.1016\/j.neurol.2015.12.010_bib0105","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/00007691-199412000-00001","article-title":"Carbamazepine and its epoxide: an open study of efficacy and side effects after carbamzepine dose increment in refractory partial epilepsy","volume":"16","author":"Semah","year":"1994","journal-title":"Ther Drug Monit"},{"issue":"8","key":"10.1016\/j.neurol.2015.12.010_bib0110","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/archneur.1990.00530080072013","article-title":"Carbamazepine-10,11-epoxide in epilepsy. A pilot study","volume":"47","author":"Tomson","year":"1990","journal-title":"Arch Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2015.12.010_bib0115","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-198611030-00001","article-title":"Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update","volume":"11","author":"Bertilsson","year":"1986","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.neurol.2015.12.010_bib0120","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/0920-1211(89)90060-0","article-title":"Factors influencing serum levels of carbamazepine and carbamazepine-10,11-epoxide in children","volume":"4","author":"Altafullah","year":"1989","journal-title":"Epilepsy Res"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378716004380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378716004380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T07:05:16Z","timestamp":1748847916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378716004380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":24,"journal-issue":{"issue":"4-5","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0035378716004380"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2015.12.010","relation":{},"ISSN":["0035-3787"],"issn-type":[{"type":"print","value":"0035-3787"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implications of metabolic parameters of carbamazepine in the therapeutic monitoring of Tunisian patients with epilepsy","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2015.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}